Login
Population (July 2005)
10m
GDP (PPP - 2004)
$70.88bn
Health expenditure (2002)
Health expenditure as proportion of GDP (2002)
Size of pharmaceutical market (sales, 2003)
Percentage of GDP spent on pharmaceuticals (2001)
Percentage of health expenditure spent on medicines (2001)
Pharmaceutical market growth rate (2002)
Local currency
Tunisian dinar (TND)
Summary: Tunisia
Tunisia enjoys the highest per capita income among countries from the Maghreb. Among achievements of the healthcare sector, given its regional context, are the unlikeliness of stock shortages, and the total eradication of several incapacitating and fatal diseases such as malaria, cholera and poliomyelitis.
The uniqueness of its pharmaceutical sector is the exclusive monopoly of medicine import reserved to the public sector. It has permitted to control the import prices and contain the costs of drug provision to hospitals and pharmacies.
As the allowed grace period has expired, Tunisia now must comply with its agreements with the European Union and the WTO.
Summary of report content
- Summary
- How is the healthcare system structured?
- What size is the pharmaceutical market?
- Are pharmaceuticals taxed?
- How are drug prices set?
- How are prices changed?
- How are drugs reimbursed?
- Is there a payback arrangement?
- Are hospital sales controlled?
- Are OTC prices regulated?
- How are pharmaceutical costs controlled?
- How are generic drugs priced?
- What are wholesale/pharmacy margins?
- Is parallel trade influential?
- What to look out for
- Glossary
- Useful Contacts
Your Basket
Your basket is currently empty.
Search News
News
07/10/2005
Tunisia and Senegal sign cooperation agreement
02/10/2005
Euro-Mediterranean health cooperation proposed
04/07/2005
Single public health insurance to be developed
Related Items